|
1
|
Patrignani P and Patrono C: Aspirin and
Cancer. J Am Coll Cardiol. 68:967–976. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chan AT, Arber N, Burn J, Chia WK, Elwood
P, Hul MA, Logan RF, Rothwell PM, Schrör K and Baron JA: Aspirin in
the chemoprevention of colorectal neoplasia: An overview. Cancer
Prev Res (Phila). 5:164–178. 2012. View Article : Google Scholar
|
|
3
|
Sostres C, Gargallo CJ and Lanas A:
Aspirin, cyclooxygenase inhibition and colorectal cancer. World J
Gastrointest Pharmacol Ther. 5:40–49. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rothwell PM, Wilson M, Elwin C-E, Norrving
B, Algra A, Warlow CP and Meade TW: Long-term effect of aspirin on
colorectal cancer incidence and mortality: 20-year follow-up of
five randomised trials. Lancet. 376:1741–1750. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bosetti C, Rosato V, Gallus S, Cuzick J
and La Vecchia C: Aspirin and cancer risk: A quantitative review to
2011. Ann Oncol. 23:1403–1415. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rothwell PM, Fowkes FGR, Belch JF, Ogawa
H, Warlow CP and Meade TW: Effect of daily aspirin on long-term
risk of death due to cancer: Analysis of individual patient data
from randomised trials. Lancet. 377:31–41. 2011. View Article : Google Scholar
|
|
7
|
Alfonso L, Ai G, Spitale RC and Bhat GJ:
Molecular targets of aspirin and cancer prevention. Br J Cancer.
111:61–67. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pedersen AK and FitzGerald GA:
Dose-related kinetics of aspirin. Presystemic acetylation of
platelet cyclooxygenase. N Engl J Med. 311:1206–1211. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bahar FG and Imai T: Aspirin hydrolysis in
human and experimental animal plasma and the effect of metal
cations on hydrolase activities. Drug Metab Dispos. 41:1450–1456.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hutt AJ, Caldwell J and Smith RL: The
metabolism of aspirin in man: A population study. Xenobiotica.
16:239–249. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bojić M, Sedgeman CA, Nagy LD and
Guengerich FP: Aromatic hydroxylation of salicylic acid and aspirin
by human cytochromes P450. Eur J Pharm Sci. 73:49–56. 2015.
View Article : Google Scholar
|
|
12
|
Grootveld M and Halliwell B:
2,3-Dihydroxybenzoic acid is a product of human aspirin metabolism.
Biochem Pharmacol. 37:271–280. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peyressatre M, Prével C, Pellerano M and
Morris MC: Targeting cyclin-dependent kinases in human cancers:
From small molecules to Peptide inhibitors. Cancers (Basel).
7:179–237. 2015. View Article : Google Scholar
|
|
15
|
Brown NR, Korolchuk S, Martin MP, Stanley
WA, Moukhametzianov R, Noble ME and Endicott JA: CDK1 structures
reveal conserved and unique features of the essential cell cycle
CDK. Nat Commun. 6:67692015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hamilton E and Infante JR: Targeting
CDK4/6 in patients with cancer. Cancer Treat Rev. 45:129–138. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Roskoski R Jr: Cyclin-dependent protein
kinase inhibitors including palbociclib as anticancer drugs.
Pharmacol Res. 107:249–275. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dachineni R, Ai G, Kumar DR, Sadhu SS,
Tummala H and Bhat GJ: Cyclin A2 and CDK2 as novel targets of
aspirin and salicylic acid: A potential role in cancer prevention.
Mol Cancer Res. 14:241–252. 2016. View Article : Google Scholar :
|
|
20
|
Ai G, Dachineni R, Kumar DR, Marimuthu S,
Alfonso LF and Bhat GJ: Aspirin acetylates wild type and mutant p53
in colon cancer cells: Identification of aspirin acetylated sites
on recombinant p53. Tumour Biol. 37:6007–6016. 2016. View Article : Google Scholar
|
|
21
|
Ai G, Dachineni R, Muley P, Tummala H and
Bhat GJ: Aspirin and salicylic acid decrease c-Myc expression in
cancer cells: A potential role in chemoprevention. Tumour Biol.
37:1727–1738. 2016. View Article : Google Scholar
|
|
22
|
Alfonso LF, Srivenugopal KS, Arumugam TV,
Abbruscato TJ, Weidanz JA and Bhat GJ: Aspirin inhibits
camptothecin-induced p21C IP1 levels and potentiates apoptosis in
human breast cancer cells. Int J Oncol. 34:597–608. 2009.PubMed/NCBI
|
|
23
|
Van Der Spoel D, Lindahl E, Hess B,
Groenhof G, Mark AE and Berendsen HJ: GROMACS: Fast, flexible, and
free. J Comput Chem. 26:1701–1718. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Senderowicz AM: Flavopiridol: The first
cyclin-dependent kinase inhibitor in human clinical trials. Invest
New Drugs. 17:313–320. 1999. View Article : Google Scholar
|
|
25
|
Sausville EA: Complexities in the
development of cyclin-dependent kinase inhibitor drugs. Trends Mol
Med. 8(Suppl): S32–S37. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Welburn JP, Tucker JA, Johnson T, Lindert
L, Morgan M, Willis A, Noble ME and Endicott JA: How tyrosine 15
phosphorylation inhibits the activity of cyclin-dependent kinase
2-cyclin A. J Biol Chem. 282:3173–3181. 2007. View Article : Google Scholar
|
|
27
|
Vane JR, Bakhle YS and Botting RM:
Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 38:97–120.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thun MJ, Jacobs EJ and Patrono C: The role
of aspirin in cancer prevention. Nat Rev Clin Oncol. 9:259–267.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dovizio M, Tacconelli S, Sostres C,
Ricciotti E and Patrignani P: Mechanistic and pharmacological
issues of aspirin as an anticancer agent. Pharmaceuticals (Basel).
5:1346–1371. 2012. View Article : Google Scholar
|
|
30
|
Lichtenberger LM, Fang D, Bick RJ,
Poindexter BJ, Phan T, Bergeron AL, Pradhan S, Dial EJ and Vijayan
KV: Unlocking aspirin's chemopreventive activity: Role of
irreversibly inhibiting platelet cyclooxygenase-1. Cancer Prev Res
(Phila). 10:142–152. 2017. View Article : Google Scholar
|
|
31
|
Patrignani P, Sacco A, Sostres C, Bruno A,
Dovizio M, Piazuelo E, Di Francesco L, Contursi A, Zucchelli M,
Schiavone S, et al: Low-dose aspirin acetylates cyclooxygenase-1 in
human colorectal mucosa: Implications for the chemoprevention of
colorectal cancer. Clin Pharmacol Ther. 102:52–61. 2017. View Article : Google Scholar
|
|
32
|
Kopp E and Ghosh S: Inhibition of NF-kappa
B by sodium salicylate and aspirin. Science. 265:956–959. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hawley SA, Fullerton MD, Ross FA,
Schertzer JD, Chevtzoff C, Walker KJ, Peggie MW, Zibrova D, Green
KA, Mustard KJ, et al: The ancient drug salicylate directly
activates AMP-activated protein kinase. Science. 336:918–922. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Klessig DF, Tian M and Choi HW: Multiple
targets of salicylic acid and its derivatives in plants and
animals. Front Immunol. 7:2062016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Manach C, Scalbert A, Morand C, Rémésy C
and Jiménez L: Polyphenols: Food sources and bioavailability. Am J
Clin Nutr. 79:727–747. 2004.PubMed/NCBI
|
|
36
|
Ganapathy V, Thangaraju M, Gopal E, Martin
PM, Itagaki S, Miyauchi S and Prasad PD: Sodium-coupled
monocarboxylate transporters in normal tissues and in cancer. AAPS
J. 10:193–199. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gervot L, Carrière V, Costet P, Cugnenc
PH, Berger A, Beaune PH and de Waziers I: CYP3A5 is the major
cytochrome P450 3A expressed in human colon and colonic cell lines.
Environ Toxicol Pharmacol. 2:381–388. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Thelen K and Dressman JB: Cytochrome
P450-mediated metabolism in the human gut wall. J Pharm Pharmacol.
61:541–558. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Paine MF, Hart HL, Ludington SS, Haining
RL, Rettie AE and Zeldin DC: The human intestinal cytochrome P450
'pie'. Drug Metab Dispos. 34:880–886. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kumarakulasingham M, Rooney PH, Dundas SR,
Telfer C, Melvin WT, Curran S and Murray GI: Cytochrome P450
profile of colorectal cancer: Identification of markers of
prognosis. Clin Cancer Res. 11:3758–3765. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Paterson JR, Blacklock C, Campbell G,
Wiles D and Lawrence JR: The identification of salicylates as
normal constituents of serum: A link between diet and health? J
Clin Pathol. 51:502–505. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Juurlink BH, Azouz HJ, Aldalati AM,
AlTinawi BM and Ganguly P: Hydroxybenzoic acid isomers and the
cardiovascular system. Nutr J. 13:632014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Arunachalam M, Mohan N, Sugadev R,
Chellappan P and Mahadevan A: Degradation of (+)-catechin by
Acinetobacter calcoaceticus MTC 127. Biochim Biophys Acta.
1621:261–265. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gao K, Xu A, Krul C, Venema K, Liu Y, Niu
Y, Lu J, Bensoussan L, Seeram NP, Heber D, et al: Of the major
phenolic acids formed during human microbial fermentation of tea,
citrus, and soy flavonoid supplements, only
3,4-dihydroxyphenylacetic acid has antiproliferative activity. J
Nutr. 136:52–57. 2006.
|
|
45
|
Seeram NP, Bourquin LD and Nair MG:
Degradation products of cyanidin glycosides from tart cherries and
their bioactivities. J Agric Food Chem. 49:4924–4929. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Paterson JR and Lawrence JR: Salicylic
acid: A link between aspirin, diet and the prevention of colorectal
cancer. QJM. 94:445–448. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kamiloglu S, Capanoglu E, Grootaert C and
Van Camp J: Anthocyanin absorption and metabolism by human
intestinal Caco-2 cells - A review. Int J Mol Sci. 16:21555–21574.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kresty LA, Mallery SR and Stoner GD: Black
raspberries in cancer clinical trials: Past, present and future. J
Berry Res. 6:251–261. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dovizio M, Bruno A, Tacconelli S and
Patrignani P: Mode of action of aspirin as a chemopreventive agent.
Prospects for Chemoprevention of Colorectal Neoplasia. Springer;
pp. 39–65. 2013, View Article : Google Scholar
|
